Significant benefits for melanoma patients have been obtained through targeted modification of tumour vasculature, immunity and inflammation, such as IFN-α (Moschos et al, 2006) and isolated limb perfusion of high-dose TNF-α therapies (Lienard et al, 1992). Here, TNF is linked to melanoma.